Company record
Celularity, Inc
1 FDA warning letter since 2023 and 0 recalls in the last 12 months.
Get an email the day FDA posts anything new about Celularity, Inc.
Warning letters
-
BiologicsCelularity, Inc
FDA warns Celularity that Interfyl is an unapproved new drug and unlicensed biological product marketed for orthopedic and wound uses.
High risk